These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24059228)

  • 1. Does erythropoietin always win?
    Cernaro V; Lacquaniti A; Buemi A; Lupica R; Buemi M
    Curr Med Chem; 2014 Mar; 21(7):849-54. PubMed ID: 24059228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
    Coronado Daza J; Martí-Carvajal AJ; Ariza García A; Rodelo Ceballos J; Yomayusa González N; Páez-Canro C; Loza Munárriz C; Urrútia G
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011122. PubMed ID: 26671531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
    Duh MS; Weiner JR; White LA; Lefebvre P; Greenberg PE
    Pharmacoeconomics; 2008; 26(2):99-120. PubMed ID: 18198931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the anaemia of chronic renal failure with recombinant erythropoietin.
    Adamson JW; Eschbach JW
    Q J Med; 1989 Dec; 73(272):1093-101. PubMed ID: 2694210
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin (rHuEPO) in the treatment of anaemia of chronic renal failure.
    Desai JD; Shah BV
    J Assoc Physicians India; 1991 Jun; 39(6):483-5. PubMed ID: 1938855
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.
    Eschbach JW
    Kidney Int; 1989 Jan; 35(1):134-48. PubMed ID: 2651751
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
    Nissenson AR; Nimer SD; Wolcott DL
    Ann Intern Med; 1991 Mar; 114(5):402-16. PubMed ID: 1992884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CPD: using evidence based clinical practice guidelines in the management of anaemia in patients with chronic renal failure.
    Price L; Osborne S
    Collegian; 2003 Jan; 10(1):35-7. PubMed ID: 15481510
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure.
    Erslev AJ; Besarab A
    Kidney Int; 1997 Mar; 51(3):622-30. PubMed ID: 9067892
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and potential applications for erythropoietin.
    Pedrazzini A
    Acta Haematol; 1992; 87 Suppl 1():2-3. PubMed ID: 1574962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of renal anemia with erythropoietin].
    Spustova V; Kovac A
    Bratisl Lek Listy; 1999 Aug; 100(8):432-8. PubMed ID: 10645031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
    Adamson JW; Eschbach JW
    Annu Rev Med; 1990; 41():349-60. PubMed ID: 2184735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.